Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name AXL over exp
Gene Variant Detail

AXL over exp (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL over exp Advanced Solid Tumor sensitive RXDX-106 Preclinical - Cell line xenograft Actionable In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells over expressing Axl in culture, resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...
AXL over exp lung non-small cell carcinoma predicted - sensitive SGI-7079 Preclinical - Cell line xenograft Actionable In a preclinical study, SGI-7079 inhibited growth of mesenchymal non-small cell lung cancer cell lines expressing high levels of AXL in culture and reduced tumor growth in xenograft models (PMID: 23091115). 23091115
AXL over exp prostate cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment in combination with Erbitux (cetuximab) synergistically inhibited proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture (PMID: 32439698). 32439698
AXL over exp prostate cancer sensitive Bemcentinib + Metformin Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). 27923843
AXL over exp head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment did not decrease proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture, and did not inhibit tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL over exp head and neck cancer sensitive Bemcentinib + Erlotinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012). 24026012
AXL over exp melanoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment inhibited viability of a BRAF wild-type melanoma cell line overexpressing Axl in culture (PMID: 35332208). 35332208
AXL over exp head and neck squamous cell carcinoma sensitive Cetuximab + Imatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gleevec (imatinib) treatment in combination with Erbitux (cetuximab) synergistically inhibited tumor growth and induced regression in an Erbitux (cetuximab)-resistant cell line xenograft model of head and neck squamous cell carcinoma overexpressing AXL (PMID: 32439698). 32439698
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT04631744 Phase II Cabozantinib Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Recruiting USA 0